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The increasing spread of drug-resistant malaria strains underscores the need for new antimalarial agents with
novel modes of action (MOAs). Here, we describe a compound representative of a new class of antimalarials.
This molecule, ACT-213615, potently inhibits in vitro erythrocytic growth of all tested Plasmodium falciparum
strains, irrespective of their drug resistance properties, with half-maximal inhibitory concentration (IC50) values
in the low single-digit nanomolar range. Like the clinically used artemisinins, the compound equally and very
rapidly affects all 3 asexual erythrocytic parasite stages. In contrast, microarray studies suggest that the MOA of
ACT-213615 is different from that of the artemisinins and other known antimalarials.
ACT-213615 is orally bioavailable in mice, exhibits activity in the murine Plasmodium berghei model and
efﬁcacy comparable to that of the reference drug chloroquine in the recently established P. falciparum SCID
mouse model.
ACT-213615 represents a new class of potent antimalarials that merits further investigation for its clinical
potential.
Malaria, caused by protozoan parasites of the genus
Plasmodium, remains a major health problem. More
than 240 million cases of malaria occur every year and
the number of annual fatalities is estimated at over
800 000 [1]. The disease accounts for 20% of all child-
hood deaths in Africa [1]. In many temperate areas
such as Western Europe or North America, malaria
has been controlled or eliminated [2]. In contrast, eco-
nomically less developed regions face 2 main problems
ﬁghting the disease: high-priced antimalarials [3] and
the increasing drug resistance of the parasite [4–8].
Therefore, the need for new and affordable drugs is
urgent and indisputable.
In 2007, the Bill and Melinda Gates Foundation un-
veiled an agenda with the overall goal of eradicating
malaria [9]. This objective is pursued in conjunction
with several other institutes such as the Roll Back
Malaria partnership of the World Health Organization
(www.rollbackmalaria.org) and one main nonproﬁt
private public partnership, Medicines for Malaria
Venture (MMV, www.mmv.org). Such strong partner-
ships were a boost for antimalarial research, leading to
an encouraging global antimalarial portfolio [10–12]
that currently contains more than 10 projects (preclin-
ical to phase IV). Furthermore, a plenitude of chemi-
cal structures, potentially serving as starting points for
new antimalarial lead substances, has been disclosed
after extensive compound screenings [13–15]. Never-
theless, since 1996, not a single new chemical class of
antimalarials has been registered [14], and the current
global portfolio of antimalarial compounds in devel-
opment relies largely on novel combinations—not
novel compounds. Since 2007, there have been very
few reports providing in-depth characterizations of
new antimalarial chemotypes, stressing the necessity
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for new drugs with novel modes of action. Recent examples of
such novel compounds are the imidazolopiperazines [16], the
spiroindolone NITD609 [17], the synthetic peroxide OZ439
[18], or the dihydroorotate dehydrogenase inhibitors [19, 20].
In the quest for a new antimalarial compound, we initially
based our activities on food-vacuolar plasmepsins (PMs) as
drug targets [21, 22]. These efforts resulted in potent PM
inhibitors that showed only moderate activity against in vitro–
cultured P. falciparum parasites [23–25], consistent with con-
current reports demonstrating that the studied food-vacuolar
PMs are not essential for parasite proliferation [26, 27]. Cell-
based antimalarial screens were thus performed to ﬁnd new
lead structures independent of molecular targets. In a library
with an assortment of aspartic protease inhibitors and com-
pounds with undeﬁned targets, novel piperazine-containing
compounds were identiﬁed. These compounds were consider-
ably more potent than the PM inhibitors and were further de-
veloped. Medicinal chemistry efforts led to improved potency
of the piperazine-containing compounds with half-maximal
inhibitory concentration (IC50) values in the low nanomolar
range. Herein we describe the in vitro and in vivo properties
of one example of this new chemotype: ACT-213615. The
compound showed a fast onset of action against all 3 asexual
erythrocytic stages of the parasite in vitro and was effective
against a panel of drug-resistant strains with IC50 values in the
range of that of artesunate, one of the most potent clinically
used antimalarials [28]. The molecular target of this novel
compound remains unknown. However, microarray data from
ACT-213615-treated in vitro cultures indicate a MOA distinct
from that of several registered antimalarials. ACT-213615 was
orally bioavailable in mice and showed activity in 2 murine
models of malaria; importantly, in the P. falciparum severe
combined immunodeﬁciency (SCID) mouse model [29], the
activity of the compound was comparable to that of the refer-
ence drug chloroquine, emphasizing the potential of this class
of compounds as new therapeutic agents for the treatment of
malaria.
METHODS
Synthesis of ACT-213615
Please see the online edition of the Journal of Infectious
Diseases for supplementary information.
In Vitro Antimalarial Activity
All Plasmodium strains were cultured according to Trager and
Jensen [30] and are described at mr4.org (resistant strains: K1,
TM90C2A, V1/S, W2, and 7G8, sensitive strains: D6, 3D7,
and NF54). IC50 values were determined in vitro by measuring
incorporation of the nucleic acid precursor [3H]hypoxanthine
[31]. In vitro time-, stage-, and concentration-dependent
effects were assessed using pyrimethamine as a stage-speciﬁc
and slow acting control, as described elsewhere [32].
Animal Experiments
In vivo efﬁcacy studies in mice were conducted at the Swiss
Tropical and Public Health Institute (Basel) according to the
rules and regulations for the protection of animal rights
(“Tierschutzverordnung”) of the Swiss “Bundesamt für Veter-
inärwesen.” They were approved by the veterinary ofﬁce of
Canton Basel-Stadt, Switzerland.
24-hour Schizont Maturation Assay (P. berghei)
In vitro (ex vivo) activity against P. berghei (GFP-transfected
ANKA strain, donated by A. P. Waters and C. J. Janse, Leiden
University, The Netherlands) was essentially measured as de-
scribed elsewhere [31] with the following modiﬁcations: Hepa-
rinized blood of a P. berghei–infected and an uninfected
(control) female NMRI mouse (ﬁnal hematocrit of 2.5%) was
used and exposed to compounds for 16 hours followed by 8
hours of [3H]hypoxanthine incorporation.
Activity Against Other Parasitic Protozoa and Cytotoxicity
Against L6 Cells
In vitro activity against T. brucei rhodesiense, T. cruzi, Leish-
mania donovani, and against L6 cells, a primary cell line
derived from mammalian (rat) skeletal myoblasts, was deter-
mined as described elsewhere [33].
Pharmacokinetics
Bioavailability of ACT-213615 in P. berghei–infected female
NMRI mice was measured after administration of a single oral
dose of 100 mg/kg in 7% Tween80/3% ethanol. Time points of
sample collections (50 µL whole blood): Group A (n = 3
mice): 0.25, 1, 4, and 24 hours; Group B (n = 3 mice): 0.5, 2, 8,
and 48 hours. Measurement of plasma concentrations: see the
online edition of Journal of Infectious Diseases for supplemen-
tary information.
In Vivo Antimalarial Activity
Efﬁcacy of ACT-213615, artesunate and chloroquine (both
from Sigma-Aldrich, Buchs, Switzerland) against P. berghei
was studied as previously described [34] with the modiﬁcation
that mice (n≥ 3) were infected with a GFP-transfected
P. berghei ANKA strain (see above) and parasitemia deter-
mined using standard ﬂow cytometry techniques. Compounds
were dissolved or suspended in 70/30 Tween80/ethanol (vol/
vol) and diluted 10 times with water before dosing. With the
single-dose regimen, blood was collected on day 3 (72 hours
after infection). Samples for the triple- and quadruple-dose
regimens were collected on day 4 postinfection. Animals were
considered cured if there were no detectable parasites on day
30 postinfection.
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ACT-213615 and chloroquine were tested in the murine
P. falciparum model essentially as described elsewhere [29].
The only modiﬁcation implemented was that daily human
blood injections (0.75 mL) were administered by the intrave-
nous route instead of the intraperitoneal route.
Microarray
See the online edition of the Journal of Infectious Diseases for
supplementary information. Raw data of microarray: GEO
database Accession No.GSE39485.
RESULTS
Discovery of ACT-213615
A diverse library of aspartic protease inhibitors and com-
pounds with undeﬁned targets was tested in search of antima-
larial molecules. In a screen against in vitro–cultured
P. falciparum, several classes of growth-inhibiting compounds
were identiﬁed, including PM inhibitors [23, 24] and some
very potent piperazine-containing compounds (not inhibiting
PMs), which were chosen for optimization. Medicinal chemis-
try efforts led to improved and promising activity, both in
vitro and in vivo, of the piperazine-containing compounds;
one example, ACT-213615 (Figure 1), is characterized in this
article. The new entity has stereospeciﬁc activity; ACT-213615
is the more active S-enantiomer (geometric mean ratio of IC50
values, R : S enantiomer = 49, 95% conﬁdence interval: 37–66,
n = 3, tested in vitro against 3D7 strain).
ACT-213615 Potently and Speciﬁcally Inhibits P. falciparum
Growth in Vitro
The in vitro activity of ACT-213615 against a panel of chloro-
quine- and pyrimethamine-resistant and -sensitiveP. falciparum
strains was determined by means of hypoxanthine incorpora-
tion assays. ACT-213615 was found to very potently inhibit
growth of all 7 tested strains (IC50 values from 0.4 to 2.7 nM) ir-
respective of the drug-sensitivity status of the parasites (Table 1).
Figure 1. Structures of ACT-213615 (B ) and its enantiomer (C ). The compound is obtained by chiral separation of the racemic precursor (A). Molecu-
lar weight: 810.96 g/mole.
Table 1. In Vitro Activity of ACT-213615 and Reference Antimalarials Against a Panel of Resistant and Sensitive Plasmodium
falciparum Strains
IC50 , mean ± SD (nM)
Isolate Origin Resistance CQ PYR AS ACT-213615
NF54 Airport, NL … 11 ± 2 18 ± 1 3.7 ± 0.5 1.0 ± 0.1
K1 Thailand CQ, PYR 303 ± 37 10 138 ± 705 2.7 ± 0.4 0.46 ± 0.04
W2 Indochina CQ, PYR 326 ± 38 13 923 ± 3525 2.4 ± 0.7 0.42 ± 0.09
7G8 Brazil PYR 137 ± 21 10 484 ± 2574 1.8 ± 0.2 1.2 ± 0.2
TM90C2A Thailand CQ, PYR 174 ± 19 19 248 ± 3876 4.6 ± 1.7 2.7 ± 0.4
D6 Sierra Leone … 16 ± 1 5.4 ± 1.3 7.1 ± 1.9 1.3 ± 0.2
V1/S Vietnam CQ, PYR 458 ± 66 21 936 ± 1072 3.2 ± 0.5 0.65 ± 0.12
Max 458 21 936 7.1 2.7
Min 11 5.4 1.8 0.42
Max/Min 42 4062 4 7
IC50 values were determined by [
3H]hypoxanthine incorporation. Data are the means ± SD of n = 3 independent experiments (each run in duplicate).
Max and Min depict the highest and lowest measured IC50 for each compound. The ratio (Max/Min) indicates the range of susceptibility to each compound.
Abbreviations: AS, artesunate; CQ, chloroquine; PYR, pyrimethamine.
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In contrast, several strains showed considerable resistance
against the control drugs chloroquine and pyrimethamine
(IC50 values from 11 to 458 nM and 5.4 to 21936 nM,
respectively). Notably, the activity of ACT-213615, and its
lack of cross-resistance, was comparable to that of the
highly potent clinically used comparator drug artesunate for
every strain tested (IC50 values for artesunate: 1.8–7.1 nM)
(Table 1).
The antiproliferative effect of ACT-213615 was observed to
be Plasmodium-speciﬁc, that is, not caused by unspeciﬁc cyto-
toxicity, as demonstrated by an at least 750-fold lower activity
against a panel of 3 different parasitic protozoa and mammali-
an L6 cells (Table 2).
ACT-213615 Is Fast Acting and Affects All Asexual Erythrocytic
Stages of the Parasite in Vitro
To examine the onset of action of ACT-213615 and determine
whether the compound shows parasite stage-speciﬁc activity,
in vitro time-, stage-, and concentration-dependent effects of
ACT-213615 were studied with synchronous cultures of P. fal-
ciparum 3D7. Growth of all 3 asexual erythrocytic stages of
the parasite (rings, trophozoites, and schizonts) was quantiﬁed
by hypoxanthine incorporation relative to untreated controls
after incubation for 1, 6, 12, or 24 hours in presence of ap-
proximately 1, 10, and 100 times the IC50 of the compound.
After each period of exposure, the compound was removed by
extensive washing. ACT-213615 rapidly reduced parasite
growth. Onset of action was detectable after 1 hour of com-
pound exposure. Furthermore, ACT-213615 equally affected
all asexual erythrocytic stages in a time- and concentration-
dependent manner (Figure 2). A fast onset of action and the
activity against all asexual erythrocytic parasite stages are rare
and highly desirable features that are shared with the artemisi-
nins [18, 28, 35, 36]. In contrast, pyrimethamine, for example,
was reported to be stage-speciﬁc and relatively slow acting
against cultured P. falciparum [36, 37].
ACT-213615 Is Efﬁcacious in Mouse Models of Malaria
In order to investigate whether the promising in vitro activity
of the compound translates into efﬁcacy in vivo, ACT-213615
was tested in 2 different mouse models.
In vivo antimalarial activity of ACT-213615 was ﬁrst
studied in the P. berghei mouse model. Prior to using animals,
in vitro (ex vivo) activity against the surrogate rodent parasite,
P. berghei, was determined in a 24-hour schizont maturation
assay, measuring hypoxanthine incorporation. ACT-213615
was more than 30 times less active against P. berghei than
against P. falciparum NF54 (geometric mean ratio of IC50
Figure 2. In vitro concentration- and stage-dependent effects of ACT-
231615 on the growth of synchronous cultures of Plasmodium falciparum
3D7 determined by [3H]hypoxanthine incorporation. Parasites were
exposed to ACT-213615 for 1, 6, 12, or 24 h at the indicated concentra-
tion, expressed as folds of IC50. After removal of the compound, para-
sites were incubated for 24 h in the presence of [3H]hypoxanthine.
Results are expressed as the percentage of growth of the respective de-
velopment stage relative to an untreated control. White bars show ring
stages, black bars show trophozoite stages, grey bars show schizont
stages. Each bar represents the mean + SD of n = 3 independent
experiments.
Table 2. In Vitro Antiprotozoal and Cytotoxic Activities of ACT-213615 and Standard Controls
IC50, mean ± SD (nM)
Experiment
Plasmodium
falciparum, K1
Trypanosoma brucei
rhodesiense
Trypanosoma
cruzi
Leishmania
donovani Cytotoxicity, L6
ACT-213615 0.46 ± 0.04 2220 ± 396 5019 ± 1341 8693 ± 882 8854 ± 3068
Standard control 303 ± 37a 15 ± 3b 1223 ± 347c 402 ± 34d 15 ± 5e
Data are the means ± SD of n = 3 independent experiments.
Standard compounds: a Chloroquine.
b Melarsoprol.
c Benznidazole.
d Miltefosine.
e Podophyllotoxin.
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values, P. berghei : P. falciparum = 38, 95% conﬁdence interval:
13–116, n = 3, both strains tested using a 24-hour assay).
In a next step, the compound was tested for its oral bioavail-
ability in P. berghei–infected NMRI mice. Plasma concentrations
of ACT-213615 (n = 3/time point) were measured by LC-MS/
MS between 0.25 and 48 hours after a single oral dose of
100 mg/kg. ACT-213615 was found to be orally bioavailable: after
2 hours, a maximal plasma concentration of 9.6 ± 1.1 µg/mL
was reached, which declined with a half-life of 5 hours
(Figure S1). Exposure (AUC0-∞) was 91.4 ± 12.7 µg/mL*h.
These results indicate that exposure of ACT-213615 in
P. berghei–infected mice should be sufﬁcient to detect antima-
larial efﬁcacy in vivo, despite the moderate activity of the com-
pound against P. berghei in vitro.
In vivo efﬁcacy studies in the P. berghei mouse model were
performed with 3 consecutive daily oral doses of 3, 10, 30,
100, 300, or 750 mg/kg of ACT-213615. In addition, 90%
effective dose (ED90) experiments were conducted applying
single oral doses. A steep dose response was observed with an
ED90 of 54.4 mg/kg, judged by the reduction of parasitemia
compared to untreated controls. Furthermore, the compound
caused dose-dependent prolongation of survival and cure at a
dose of 3 × 750 mg/kg (Table S1). No acute toxicity was ob-
served. Considering that ACT-213615 was about 38-fold more
potent in vitro against P. falciparum than against P. berghei
(see above), it was concluded from the results of the P. berghei
mouse model that ACT-213615 should be highly active
against P. falciparum in vivo.
The in vivo efﬁcacy against P. falciparum was assessed in
the SCID mouse P. falciparum model. This recently estab-
lished model [29] uses SCID mice engrafted with human
erythrocytes, offering the possibility to investigate the actual
target parasite P. falciparum in vivo. Four consecutive daily
oral doses of 2, 5, 10, and 20 mg/kg of ACT-213615 were ad-
ministered. Quantiﬁcation of parasitemia revealed a steep dose
response and the compound was found to be very potent
(ED90 = 8.4 mg/kg), comparable to the standard control chlo-
roquine (ED90= 6.4 mg/kg) (Table 3). Again, no acute toxicity
was observed.
Mode of Action
As the new chemotype was discovered in a cellular screen, the
mode of action (MOA) of ACT-213615 is unclear. To date,
PM I, II, and IV could be ruled out as targets based on in
vitro assays (IC50 values: 56 200, 45 400, and >100 000 nM, re-
spectively, n = 1; see the online Journal for supplementary in-
formation). In order to gain more information about the
MOA and a putative target, genome-wide expression changes
induced by treatment with ACT-213615 were investigated in
P. falciparum and compared to previously established changes
in gene expression induced by 20 different compounds with
antimalarial activity [38]. For this microarray study, highly
synchronized 3D7 P. falciparum parasites were treated in vitro
with an IC90 of ACT-213615 and control samples with DMSO
only, starting at t0 = 32 hours postinfection for 1, 2, 4, 6, and 8
hours.
ACT-213615 altered the mRNA levels of 552 genes by at
least 2-fold at ≥ 2 time points (Figure 3A). In total, 407 of
these genes were up-regulated and 145 down-regulated. Func-
tional enrichment analysis revealed statistical overrepresenta-
tion of several basic cellular and metabolic pathways among
the up-regulated genes (Figure 3B). These include protein syn-
thesis (ribosomal subunits and assembly factors) and post-
translational modiﬁcations of proteins (N-myristoylation,
S-acylation and prenylation). Furthermore, a major lipid me-
tabolism pathway (phosphatidylethanolamine and phosphati-
dylserine metabolism) and a total of 18 protein kinases were
found to be up-regulated by ACT-213615. On the other hand,
treatment with the compound caused signiﬁcant down-regula-
tion of numerous components of the merozoite invasion
machinery. Nonetheless, a speciﬁc MOA could not be derived
from the above results. The gene expression data could,
however, be used to differentiate the MOA of ACT-213615
from that of known antimalarial compounds. It was of partic-
ular interest to investigate whether the strikingly similar phar-
macological effects of ACT-213615 and the artemisinins (see
above) derive from a similar or a different MOA. Hu and
coworkers [38] have recently characterized and proﬁled gene
expression patterns induced by 20 diverse small molecular in-
hibitors and registered antimalarial drugs. The comparison of
the transcriptional response induced by ACT-213615 to these
20 established proﬁles is summarized in Figure 3C and 3D.
Hierarchical clustering analysis displayed as a principal coor-
dinate plot (Figure 3C) or a dendrogram (Figure 3D) revealed
4 principal groups of the 20 chemical perturbations on the
basis of similarities in induced expression patterns. ACT-
213615 clustered with a subset of the perturbations including
Table 3. In Vivo Activity of ACT-213615 and Chloroquine in the
Plasmodium falciparum Mouse Model
Oral dose,a mg/kg
ACT-213615
activity,b %
Chloroquine
activity,b %
4 × 2 8 68
4 × 5 64 86
4 × 10 94 94
4 × 20 95 Not tested
a P. falciparum-infected mice (mean of n = 3 animals); formulation: 7%
Tween80/3% ethanol; animals were dosed once/day 3, 4, 5, and 6 days
postinfection.
b Reduction of parasitemia compared to untreated controls. Assessed 96 h
after the first treatment (4-day test by Peters). Parasitemia of untreated
controls (means of n = 5 animals) before first treatment: 1.1%; after 96 h:
14.4%.
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Figure 3. Analyses of genome-wide transcriptional response of P. falciparum parasites to treatment with ACT-213615. Highly synchronized 3D7
schizonts were treated with ACT-213615 (IC90) and control samples with DMSO only. RNA was collected after 1, 2, 4, 6, and 8 h of treatment. A, The
heat map represents genes found to be differentially expressed by at least 2-fold at more than one time point. B, The pie charts show signiﬁcantly
enriched pathways under treatment (P < .05) identiﬁed by functional enrichment analysis. Depicted is the fraction of differentially expressed genes that
are within (colored) and not within (gray) the enriched functional pathways, the number and percentage of genes in each cluster are indicated. C,
3-dimensional principal coordinate plot in which distances between points indicate the degree of similarity between transcriptional proﬁles of individual
antimalarial compounds. D, Dendrogram of hierarchical clustering of transcriptional responses to compounds revealed 4 distinct clusters. The color code
is consistent in panels C and D.
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generic protein kinase inhibitors such as staurosporine and
ML-7 on one side and retinol A or the serine protease inhibi-
tor PMSF on the other side. Importantly, ACT-213615 was
not found in the same cluster as artemisinin (Figure 3C and
3D) despite the similar in vitro properties of these 2 com-
pounds. In addition, the MOA of ACT-213615 also appeared
to be different from that of chloroquine and quinine which
clustered with artemisinin in the above analysis. Microarray
data were validated using real-time quantitative PCR (qPCR)
(Figure S2).
DISCUSSION
In a cell-based screen, we identiﬁed a new pharmacophore
with potent antimalarial activity. Medicinal chemistry efforts
led to the lead compound ACT-213615. In vitro, this com-
pound inhibits erythrocytic P. falciparum growth of drug-
sensitive and drug-resistant strains at single-digit nanomolar
concentrations, comparable to the reference antimalarials
chloroquine and artesunate. We have further demonstrated
that ACT-213615 is highly effective in vivo against P. falcipa-
rum in the SCID mouse model (ED90= 8.4 mg/kg), where its
activity after oral dosing was comparable to that of chloro-
quine. These results suggest that ACT-213615 represents a
class of molecules that has the potential to be further devel-
oped for clinical use against malaria.
The novel pharmacophore also showed activity in the
P. berghei mouse model, including prolongation of survival
and cure. The effective dose in the P. berghei model was con-
siderably higher than in the P. falciparum mouse model
(ED90= 54.4 mg/kg). This difference in effectiveness between
the 2 models can be explained by the approximate 38-fold dif-
ference in in vitro potency that was observed against the 2
parasite species. The result implies that testing compounds in
vivo with the surrogate parasite P. berghei can in some cases
lead to misguided elimination of compounds from drug dis-
covery pipelines due to a perceived lack of efﬁcacy, despite sig-
niﬁcant potency against P. falciparum in vitro.
Pharmacokinetic studies in P. berghei–infected NMRI mice
revealed that ACT-213615 is orally bioavailable and has a
short plasma half-life of 5 hours. A short plasma half-life sug-
gests a low probability of resistance development in vivo,
because the time of exposure to a sublethal concentration of
the molecule would be short. Artemisinins, which are the
backbone of antimalarial chemotherapy today [8], have short
plasma half-lives as well [39], and a low propensity to develop
resistance in vivo. However, reduced sensitivity to artesunate
has recently been observed at the Thai/Cambodian border
[6, 7]. In order to impede resistance development in vivo, the
following strategies are recommended: Antimalarials should
be developed as combinations of compounds that act through
different MOAs [40], whereby molecules with a short half-life
seem favorable and could be combined with compounds that
display longer half-lives [41].
In vitro, ACT-213615 showed a fast onset of action (detect-
able after 1 hour) and equal potency against all asexual eryth-
rocytic parasite stages—qualities reminiscent of the highly
potent and clinically used artemisinins [28, 35, 36]. Rapid ef-
fectiveness against all asexual erythrocytic stages is an essential
characteristic of a new antimalarial, because it leads to a fast
reduction of a mixed parasite population and, likewise, might
reduce recrudescence as it helps prevent the escape of an oth-
erwise unaffected stage during a short-time exposure. Efﬁcacy
against all asexual erythrocytic stages also represents a desir-
able attribute for combination therapies, because it quickly
reduces the parasite load and complements a possible deﬁcit
of the combination partner with respect to stage-speciﬁcity.
Finally, a fast onset of action potentially shortens treatment
times.
The MOA of ACT-213615 currently remains unknown, but
involvement of a speciﬁc target is suspected on the basis of
enantiomer selectivity of the compound, evidence of parasite-
speciﬁc activity, and absence of nonspeciﬁc cytotoxicity. In
order to gain insight into cellular pathways affected in treated
parasites, and to obtain information about the MOA and/or
targets of the compound, a microarray study was performed
assessing transcriptional changes induced by treatment with
ACT-213615 in synchronized erythrocytic cultures of P. falcip-
arum. It has previously been shown that perturbations
induced by chloroquine [38, 42], antifolates [43], or certain
protease inhibitors have only minimal effect on Plasmodium
transcription, whereas other compounds such as protein
kinase inhibitors induce high-amplitude mRNA changes [38].
Overall, however, all transcriptional responses, regardless of
their amplitude, have some degree of biological relevance with
functionally related genes being induced by particular pertur-
bations. Functional enrichment analysis of deregulated genes
in erythrocytic P. falciparum under treatment with ACT-
213615 in vitro revealed an overrepresentation of several path-
ways. In the case of up-regulated genes, these pathways were,
for example, associated with lipid metabolism and kinase-
dependent signaling, providing starting points for speciﬁc
MOA studies. Down-regulation, on the other hand, was pre-
dominantly observed for components required for merozoite
invasion, suggesting that the parasite slows or halts its cell
cycle progression under treatment with ACT-213615. Never-
theless, it was not possible to unambiguously identify a single
likely target or pathway affected by ACT-213615.
Our microarray data, however, indicate that the MOA of
ACT-213615 differs from that of several existing antimalarials,
importantly artemisinin, chloroquine, and quinine. These
drugs group together and are separated from ACT-213615
after hierarchical clustering analysis based on similarity in
induced expression patterns. In contrast, ACT-213615
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clustered with the protein kinase inhibitors staurosporine and
ML7, with retinol A, and with the serine protease inhibitor
PMSF. It could thus be speculated that ACT-213615 may also
interfere with the largely unknown pathways of P. falciparum
affected by those compounds. Additional studies to expand on
these ﬁndings and to discover a molecular target of ACT-
213615 are planned.
Artesunate and ACT-213615 share the fast onset of action
and equal potency against all asexual erythrocytic parasite
stages but differ in their MOA on the basis of the above hier-
archical clustering analysis of the microarray data. This analy-
sis indicates that chloroquine and quinine act differently from
ACT-213615 as well. Among other currently used antimalari-
als, one can also rule out that stage-speciﬁc and slow-acting
antimalarials, such as pyrimethamine [36, 37], share the MOA
with ACT-213615. These observations demonstrate that ACT-
213615 could potentially be combined with all of these above
antimalarial drugs and that the combination would fulﬁll the
recommendation that the 2 combination partners act indepen-
dently [40].
In spite of recent and alarming reports of resistance [6, 7],
artemisinin-based compounds remain the current mainstay of
antimalarial treatment [8]. The excellent effectiveness of these
molecules is largely attributable to their potency, their fast
onset of action, and their activity against all asexual erythro-
cytic stages [18, 28, 35, 36]. These favorable properties of the
artemisinins are shared by ACT-213615, together with the
short plasma half-life [39]. Therefore, if the MOA of ACT-
213615 is conﬁrmed to be distinct from that of the peroxides,
ACT-213615 or analogs of the same chemical class have the
potential to be used as substitutes of the artemisinins in com-
bination with compounds exhibiting longer plasma half-lives.
We conclude that ACT-213615 represents a potent new an-
timalarial chemotype that exhibits in vitro and in vivo activity
comparable to chloroquine, appears to have a novel mode of
action, and acts quickly and independently of asexual erythro-
cytic stages. Further research and development activities with
this chemical class are warranted.
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